More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$53941388
EPS
-2.32
P/E ratio
--
Price to sales
2.33
Dividend yield
--
Beta
1.69082
Previous close
$3.20
Today's open
$3.28
Day's range
$2.77 - $3.66
52 week range
$2.77 - $9.82
show more
CEO
Jayson Rieger
Employees
76
Headquarters
West Chester, PA
Exchange
NASDAQ Capital Market
Shares outstanding
17178786
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Verrica Pharmaceuticals Q3 Earnings Call Highlights
Verrica Pharmaceuticals NASDAQ: VRCA reported record quarterly U.S. revenue for its molluscum treatment YCANTH in the third quarter of 2026, even as total revenue fell from a year earlier and its net loss widened.
MarketBeat • Nov 13, 2026

Verrica Pharmaceuticals Inc. (VRCA) Q3 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 13, 2026

Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
– Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million –
GlobeNewsWire • Nov 12, 2026

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
WEST CHESTER, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in London.
GlobeNewsWire • Nov 10, 2026

Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
WEST CHESTER, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m.
GlobeNewsWire • Nov 5, 2026

Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
– Company's achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now available to support continued growth of the YCANTH® business and advancement of the Company's global Phase 3 common warts program through topline data readouts, the first of which is expected in Q1'27 – WEST CHESTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it has achieved the pre-defined revenue, growth and operational milestones required to increase the maximum commitment amount under its credit facility with an entity controlled by Paul B.
GlobeNewsWire • Oct 22, 2026

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –
GlobeNewsWire • Sep 30, 2026

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
GlobeNewsWire • Sep 10, 2026

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C.
GlobeNewsWire • Sep 8, 2026

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment, with topline data currently expected in mid-2027 – WEST CHESTER, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced completion of enrollment of the first pivotal clinical trial (COVE-2) of its global Phase 3 program evaluating YCANTH® (VP-102) for the treatment of common warts.
GlobeNewsWire • Aug 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Verrica Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.